Company news

Exelixis, Inc. news in 2025

Exelixis, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

December 2, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

November 5, 2025

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 3, 2025

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 20, 2025

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

October 19, 2025

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

October 17, 2025

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

August 28, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

August 26, 2025

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

July 27, 2025

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

July 23, 2025

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

July 13, 2025

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

June 21, 2025

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

June 19, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 21, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 21, 2025

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

May 6, 2025

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

April 28, 2025

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

March 25, 2025

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

March 24, 2025

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

February 24, 2025

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

February 19, 2025

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

February 14, 2025

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

February 12, 2025

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

February 10, 2025

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

January 27, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

January 24, 2025

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

January 23, 2025

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

January 11, 2025

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

January 8, 2025

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

January 5, 2025

Calls in 2025

Decks in 2025